Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
5.52(c) 5.37(c) 5.38(c) 5.41(c) 5.73 Last
1 217 689 816 795 694 679 510 116 2 430 269 Volume
+1.47% -2.72% +0.19% +0.56% +5.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 53,4 M - -
Net income 2021 -225 M - -
Net cash position 2021 96,4 M - -
P/E ratio 2021 -2,47x
Yield 2021 -
Sales 2022 75,9 M - -
Net income 2022 -211 M - -
Net cash position 2022 205 M - -
P/E ratio 2022 -2,92x
Yield 2022 -
Capitalization 586 M 586 M -
EV / Sales 2021 9,17x
EV / Sales 2022 5,02x
Nbr of Employees 304
Free-Float 77,3%
More Financials
Company
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule... 
Read more
More about the company
Ratings of Epizyme, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about EPIZYME, INC.
09/15EPIZYME : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Pr..
AQ
09/14EPIZYME : Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be P..
BU
08/23EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/20EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16EPIZYME : FIFTH AMENDMENT TO LEASE (Form 8-K)
PU
08/16EPIZYME, INC. : Entry into a Material Definitive Agreement, Financial Statements..
AQ
08/10EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price ..
MT
08/10EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintain..
MT
08/10EPIZYME : Wedbush Cuts Epizyme's Price Target to $12 From $26, Citing 'Lower-Tha..
MT
08/09EPIZYME : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/09EPIZYME : and HUTCHMED Announce Strategic Collaboration to Develop and Commercia..
AQ
08/09EPIZYME : Q2 Loss Widens, Revenue Rises; Company Names Grant Bogle as New CEO - ..
MT
08/09EPIZYME, INC. : Entry into a Material Definitive Agreement, Results of Operation..
AQ
08/09EPIZYME : Q2 Earnings Snapshot
AQ
08/09EPIZYME : Announces CEO Succession
BU
More news
News in other languages on EPIZYME, INC.
2020Roche erhält US-Zulassung für Cobas Diagnostiktest bei Follikulärem Lymphom
2020ROCHE : test Cobas validé par la FDA contre le lymphome folliculaire
More news
Analyst Recommendations on EPIZYME, INC.
More recommendations
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 5,41 $
Average target price 11,14 $
Spread / Average Target 106%
EPS Revisions
Managers and Directors
Grant C. Bogle President, Chief Executive Officer & Director
Matthew E. Ros Chief Financial Officer
David M. Mott Chairman
Shefali Agarwal Executive VP, Chief Medical & Development Officer
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-50.18%553
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.83%48 539